Streetbeat News

Regulatory

MRSN

Mersana Therapeutics has announced a partial clinical hold on its UP-NEXT and UPGRADE-A clinical trials. The hold is due to safety concerns raised by the FDA, which requires additional information before allowing the trials to proceed.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 11:31 am

CRVS

Corvus Pharmaceuticals announced updated data from its CPI-818 Phase 1/1B trial in solid and hematological cancers, demonstrating the potential of ITK inhibition and absolute lymphocyte count biomarker in T cell lymphoma.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 11:21 am

EWJ

EWY

SPY

North Korean missile reportedly landed inside Japan's Exclusive Economic Zone, according to NHK citing a government source.

Portfolio Pulse from Charles Gross

June 15, 2023 | 11:17 am

BYDDF

FXI

HMC

VLKAF

China's Industry Ministry has announced a six-month campaign to promote sales of New Energy Vehicles (NEVs) in rural areas, inviting companies like BYD, Honda, and Volkswagen to participate.

Portfolio Pulse from Charles Gross

June 15, 2023 | 11:15 am

CTSO

Cytosorbents received a recommendation from the Independent Data and Safety Monitoring Board to complete the pivotal STAR-T trial without modifications. The trial evaluates the ability of DrugSorb-ATR to reduce perioperative bleeding in patients undergoing cardiothoracic surgery.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 11:13 am

TNXP

Tonix Pharmaceuticals announced the publication of Phase 3 RELIEF trial results for TNX-102 SL, a non-opioid treatment for fibromyalgia management. The study showed significant reductions in daily pain, improved sleep, and reduced fatigue, with the treatment being safe and well-tolerated.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 11:09 am

INVE

Identiv, Inc. (NASDAQ:INVE) has been granted FedRAMP Marketplace Authorization for its cloud-based Hirsch Velocity security management software, Velocity Vision video management system, and Hirsch Mx Controller products after a rigorous multi-year assessment process.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 11:06 am

IOVA

Iovance Biotherapeutics announced the first patient has been randomized in the TILVANCE-301 Phase 3 trial, comparing lifileucel plus pembrolizumab versus pembrolizumab alone in frontline advanced melanoma treatment.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 11:04 am

ADBE

AMD

JBL

KR

LEN

NVDA

PLTR

QQQ

SPY

TSLA

Nasdaq futures slide as traders react to the Fed's decision to hold interest rates steady, with some analysts comparing the current scenario to early 2007. Economic data on consumer spending, job market, and manufacturing activity, as well as a rate decision from the European Central Bank, will likely drive action on Wall Street today. Tech stocks, including Tesla, Nvidia, and AMD, are under selling pressure in premarket trading.

Portfolio Pulse from Shanthi Rexaline

June 15, 2023 | 10:41 am

HL

Hecla Mining Company plans to restart its Casa Berardi mine on June 15th following the partial lifting of Quebec's ban on access to the mine's road. The company expects to resume normal production rates soon and will update the impact of the suspension and restart on production and cost guidance in the Q2 earnings release.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 10:34 am